secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2026-06-29T21:02:44+00:00
Accession:  0001213900-26-073184
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics CMO Leonardo Viana Nicacio resigns effective June 26, 2026
-------------------------------------------------------------------------------

- Leonardo Viana Nicacio, M.D., resigned as Chief Medical Officer to pursue other opportunities.
- Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, assumes his duties.
- Jacqueline Zummo, Ph.D., Chief R&D Officer, will oversee the clinical development function.
- Departure is effective June 26, 2026; no other officer changes disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026073184/0001213900-26-073184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026073184/ea0296286-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-073184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer